Novel Treatment Review (NTR) Working Group
The haemophilia treatment landscape is fast evolving, with many new and innovative therapies in the final stages of development or being marketed in Europe. To help our members navigate these changes, the EHC has developed a publication, the Novel Treatment Review (NTR) issued twice a year with the latest therapeutic developments.
The work of the NTR Working Group is supported by Roberta Sadauskaite, EHC Public Policy Lead.
Read the NTRs on the EHC Academy
EHC NTR Working Group is composed of:
Dr Paul Batty
United Kingdom
University College London
Prof Jan Blatny
Czech Republic
Consultant Haematologist and Lead Clinician at the Department of Paediatric Haematology, Centre for Thrombosis and Haemostasis at the Children’s University Hospital Brno
Prof Ana Boban
Croatia
Head of Haemophilia Centre at the University Hospital Centre Zagreb, Professor of Internal Medicine at the School of Medicine of the University of Zagreb
Panagiotis Christoforou
Greece
Steering Committee Member
Miguel Crato
Portugal
President
Radoslaw Kaczmarek
Indiana University School of Medicine, Indianapolis, USA
Post-doctoral Research Associate
Ilmar Kruis
The Netherlands
Dutch EHC NMO
Dr Maria Elisa Mancuso
Italy
MAG Chair, Centre for Thrombosis and Haemorrhagic Diseases, IRCCS Humanitas Research Hospital and Humanitas University Rozzano
Brian O’Mahony
Chief Executive of the Irish Haemophilia Society, Dublin, Ireland
Former President of the EHC
David Page
Canada
Canadian Haemophilia Society
Uwe Schlenkrich
Germany